Author

E. W. Verschuren

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 5

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 4 Approach:experimental assay· 4 Organism:human· 4 Assay:bulk RNA-seq· 3 Research Focus:cancer & tumor microenvironment· 3 Organism:mouse· 3 Research Focus:cell signaling & trafficking· 2 Approach:benchmark study· 1

Frequent Co-Authors

A. Hemmes· 4 shared J. Bao· 4 shared N. Linnavirta· 3 shared A. Knuuttila· 2 shared J. Räsänen· 2 shared K. Wennerberg· 2 shared M. I. Mäyränpää· 2 shared S. Talwelkar· 2 shared

Activity by Year

2020-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

A. Hemmes

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

A Community Challenge to Predict Clinical Outcomes After Immune Checkpoint Blockade in Non-Small Cell Lung Cancer

M. Mason, O. Lapuente-Santana, A. S. Halkola, W. Wang, R. Mall, X. Xiao, J. Kaufman, J. Fu, J. Pfeil, J. Banerjee, V. Chung, H. Chang, S. D. Chasalow, H. Y. Lin, R. Chai, , B. G. Vincent

The paper evaluates predictive models for immune checkpoint inhibitor outcomes in NSCLC using clinical trial data from two RCTs, finding that models combining PD-L1, TMB, and immune signatures outperform single biomarkers.

Journal of Translational Medicine · Feb 21, 2024Peer-reviewedCancer Biology

Development of an adenosquamous carcinoma histopathology-selective lung cancer graft model

I. A. K. Lähdeniemi, J. R. Devlin, A. S. Nagaraj, S. Talwelkar, J. Bao, N. Linnavirta, C. Seref Vujaklija, E. A. Kiss, A. Hemmes, E. W. Verschuren

This paper develops a lung cancer graft model that recapitulates histopathology-specific tumor phenotypes and demonstrates histopathology-selective phenotypic dominance over genetic drivers.

bioRxiv · Aug 23, 2022 · PreprintCancer Biology

PI3Kβ inhibition restores ALK inhibitor sensitivity in ALK-rearranged lung cancer

K. Wennerberg, E. W. Verschuren, S. Talwelkar, M. I. Mäyränpää, J. Schüler, N. Linnavirta, A. Hemmes, S. Adinolfi, M. Kankainen, W. Sommergruber, A.-L. Levonen, J. Räsänen, A. Knuuttila

The paper identifies PI3Kβ as a mediator of resistance to ALK inhibitors in ALK-rearranged lung cancer and shows that combining ALK and PI3Kβ inhibitors overcomes resistance.

bioRxiv · Mar 18, 2021 · PreprintCancer Biology

The role of SOX9 in non-small cell lung cancer progression is histopathology-selective.

E. W. Verschuren, J. Bao, K. Närhi, A. Teodosio, A. Hemmes, N. M. Linnavirta, M. I. Mäyränpää, K. Salmenkivi, J. Le Quesne

This study shows SOX9 has different roles in NSCLC progression depending on histopathology, promoting papillary adenocarcinoma but suppressing squamous metastasis.

bioRxiv · Nov 23, 2020 · PreprintCancer Biology

Functional diagnostics using fresh uncultured lung tumor cells to guide personalized treatments

S. S. Talwelkar, M. I. Mäyranpää, L. Soraas, S. Potdar, J. Bao, A. Hemmes, N. Linnavirta, J. Lomo, J. Räsänen, A. Knuuttila, K. Wennerberg, E. W. Verschuren

This study uses fresh uncultured lung tumor cells to assess drug responses and guide personalized treatment, showing clinical benefit in a refractory cancer case.

bioRxiv · Aug 12, 2020Cancer Biology